Anti-Fibrinolytics Trialists Collaboration (ATC)

What is the Anti-Fibrinolytics Trialists Collaboration?

The Anti-fibrinolytics Trialists Collaboration (ATC) is an international collaboration to conduct individual patient data meta-analyses of results from randomised trials of anti-fibrinolytics versus placebo.

The ATC has been set up to address important clinical questions regarding the effects of anti-fibrinolytics that cannot be answered by individual trials or by standard meta-analyses based on aggregate data.

Click HERE to read the ACT protocol 

Who are involved ?

The lead investigators of all completed and ongoing high quality trials of anti-fibrinolytics that involve 500 or more patients are invited to join the collaboration and contribute individual patient data.

The ATC is co-ordinated from Clinical Trials Unit at the  London School of Hygiene & Tropical Medicine

Participating Trials

The following trials of anti-fibrinolytics involving 500 or more patients have agreed to join the collaboration

ATACAS Trial: Aspirin and Tranexamic Acid for Coronary Artery Surgery Trial 

CRASH-2: Results showed that tranexamic acid safely reduced the risk of death in bleeding trauma patients

CRASH-3: The CRASH-3 trial is the first evidence of a drug which can prevent death following Traumatic Brain Injury (TBI)

HALT-IT: Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial 

PATCH: Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage 

POISE-3: PeriOperative ISchemic Evaluation-3 Trial

ROC-TXA – Prehospital Tranexamic Acid Use for Traumatic Brain Injury 

TICH-2 Trial: Tranexamic Acid for Intracerebral Haemmorhage

TRAAP: Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery

TRAAP2: TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery 

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial (

WOMAN Trial: Tranexamic acid for the treatment of postpartum haemorrhage: An international, randomised, double blind, placebo controlled trial. The WOMAN trial showed that if given within 3 hours, TXA can reduce the risk of death due to bleeding by one third

WOMAN-2 Trial: Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: an international, randomised, double-blind, placebo controlled trial

Contact Details

For more information, please contact: 

Katharine Ker, ATC co-ordinator
Clinical Trials Unit
London School of Hygiene & Tropical Medicine
Keppel Street
London WC1E 7HT, UK